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1 
Abstract 
The negative regulatory domain (NRD) of the p53 tumor suppressor is intrinsically disordered. It 
contains several post-translational modification (PTM) sites that are important for regulation of 
p53 activity. Calcium-dependent binding of dimeric S100B(ββ) to p53-NRD blocks access to 
these PTM sites and disrupts the p53 tetramer to inhibit p53 activation. Previous NMR structural 
studies have suggested that p53-NRD folds into a stable helix upon binding to S100B(ββ). 
Intriguingly, despite the well-converged and stably folded nature of the NMR structure 
ensemble, experimentally resolved intermolecular NOEs are extremely weak; most have 5−6 Å 
upper bounds, and mainly involve the C-terminal segment of p53-NRD. Such a systematic lack 
of strong intermolecular NOEs could suggest that the p53/S100B(ββ) interface is more dynamic 
than currently believed. Indeed, extensive atomistic simulations in explicit solvent (with 1.0 μs 
total effective sampling) revealed large heterogeneity in the S100B(ββ)-bound conformation of 
p53-NRD. Helix unwinding at the C-terminus allows key hydrophobic residues (Leu383 and 
Phe385) to make more extensive intermolecular contacts, whereas the highly helical N-terminus 
displays substantial flexibility in packing with S100B(ββ). Importantly, the predicted 
heterogeneous ensemble as a whole is highly consistent with experimental intermolecular NOEs, 
although many conformational sub-states coexist and individual sub-states satisfy only subsets of 
the NOE restraints. Furthermore, the simulated ensemble provides similar shielding of key PTM 
sites to support p53 inhibition. This study not only provides new insights into the structural basis 
of the p53/S100B(ββ) recognition, but also highlights the importance of recognizing dynamic 
complexes in structural studies of IDP interactions. 
2 
Introduction 
Cellular signaling and regulation are frequently mediated by proteins that lack stable tertiary 
structures under physiological conditions1-3. Such intrinsically disordered protein (IDPs) tend to 
be enriched with charged and polar residues and at the same time lack large hydrophobic 
residues that are needed for independent folding4. As a result, the native states of IDPs 
correspond to ensembles of heterogeneous and dynamic conformations instead of stably folded 
structures. Sequence analysis has revealed that intrinsic disorder is highly prevalent in 
proteomes, with about one-third of eukaryotic proteins predicted to contain disordered segments 
of >40 residues5. The prevalence of intrinsic disorder suggests that conformational heterogeneity 
(and flexibility) confer important functional advantages, especially in cellular signaling and 
regulation. Many potential benefits of intrinsic disorder have been discussed, such as larger 
binding surface areas, inducibility by posttranslational modifications (PTMs), and structural 
plasticity for binding multiple partners6-9. Interestingly, regulatory IDPs frequently fold into 
stable structures upon specific binding10. Such coupled binding and folding allows weaker 
binding to be achieved without compromising specificity, as the entropic cost of folding offsets 
the stabilization effects of forming many specific contacts. A reduced binding affinity, in turn, 
allows higher dissociation rates, which could be an important advantage in signaling and 
regulation11. 
Coupled binding and folding provides a convenient framework for understanding the structural 
basis of IDP recognition and regulation, and it has been one of the primary focuses in IDP 
studies10;12;13. Yet, examples have began to emerge where substantial conformational 
heterogeneity, and sometimes full disorder of the entire binding domain, persists in the bound 
states14-16. This led Tompa and Fuxreiter to suggest that the concept of intrinsic disorder needs to 
be extended to include protein complexes, arguing that “fuzziness” in the bound state could add 
“adaptability, versatility and reversibility to the binding of proteins and thereby an ease of 
regulation in protein-protein interactions”14. Such fuzzy complexes could include “static” and/or 
“dynamic” disorder14. A complex with static disorder, such as Tcf4/β-catenin17, samples a 
multitude of alternative folded conformations; whereas a complex with “dynamic” disorder 
contains unstructured segments, either as linkers between folded binding domains (“clamp” 
model) or as flanking tails of a globular binding domain (“flanking” model). In extreme cases, 
the entire binding domain could remain disordered in the bound state, and recognition relies 
completely on transient contacts. Examples of such “random” or “disordered” complexes include 
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the oligomeric state of the cytoplastimic domains of T-cell receptor ζ–chains18 and the Sic1/Cdc4 
complex19;20. Several examples also exist where biological activities appear to be mediated by 
interactions free of primary sequence constraints14. The implication is that these complexes are 
disordered and do not rely on strict complementarity at the binding interface.   
The recognition of the potential prevalence of disorder in protein complexes is an important one. 
It requires broader consideration of how specific interactions of IDPs might be realized and 
regulated. For complexes with dynamic disorder14, establishing the structural basis of recognition 
becomes more involved, beyond obtaining their high-resolution structures using either X-ray 
crystallography or nuclear magnetic resonance (NMR); instead, conformational ensembles are 
required. Unfortunately, resolving heterogeneous protein conformational ensembles is a 
challenging problem that is often fundamentally limited by underdetermination (that is, the 
number of experimental restraints is insufficient to uniquely define the accessible conformational 
space)21-23. On the other hand, neglecting potential conformational heterogeneity in the bound 
state, such as due to lack of awareness of fuzzy complexes, could lead to misleading structural 
interpretations. It can be particularly problematic for ensemble methods such as NMR and 
Förster resonance energy transfer (FRET), where a set of independent structural restraints are 
first determined and then used to calculate multiple structures using restrained molecular 
dynamics protocols24. Neglecting potential disorder during structural calculation will generate 
overly ordered conformations with structural features that do not necessarily co-exist23. 
The tumor suppressor p53 regulates many genes involved in cell cycle and apoptosis and is 
arguably one of the most important proteins in cancer25; for example, over 50% of human 
cancers involve some alteration of p53 activities26. At the same time, p53 is also one of the most 
extensively studied IDPs, with multiple intrinsically disordered regulatory domains that mediate 
p53’s interactions with many other proteins27. The C-terminal negative regulatory domain (NRD) 
(residues 367−392), in particular, is one of the few IDPs that have been experimentally shown to 
be able to fold into distinct structures upon specific binding to different targets, including α-
helix, β-strand and two distinct loops9.  One of the structures involves binding to Ca2+-loaded 
dimeric S100B(ββ), which blocks access to several phosphorylation and acetylation sites in p53-
NRD and thus inhibits p53 oligomerization and transcriptional activity28. The level of S100B 
protein is correlated with malignant melanoma, and is often used as a diagnostic cancer marker29. 
The p53/S100B interaction can also be targeted by small molecule inhibitors for restoring p53 
activity in cancer therapeutics30;31. 
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A previous NMR structural study32 suggested that p53-NRD folded into a short helix and formed 
a structurally stable complex when bound to S100B(ββ) (see Fig. 1). For example, the averaged 
root mean square deviations (RMSDs) of the NMR structure ensemble (PDB: 1dt7) from the 
mean structure are only 0.61 Å for all ordered backbone atoms and 1.44 Å when including all 
ordered heavy atoms32. Curiously, most assigned intermolecular nuclear Overhauser effects 
(NOEs) are extremely weak. Out of a total of 33 unique intermolecular NOEs (see Table 1), 20 
were assigned an upper bound of 6 Å and 11 others an upper bound of 5 Å. There are only two 
medium/weak intermolecular NOEs assigned, both involving p53 Leu383. Closer examination of 
the NMR ensemble revealed significant uncertainty in side chain packing at the interface, with 
only a few intermolecular contacts consistently observed within the 40-member ensemble (e.g., 
see Fig. 2A and Table S1). It also appears that a stably formed helix spanning p53 residues 376–
387 would hinder formation of extensive hydrophobic contacts between p53 nonpolar side chains 
(mainly Leu383 and Phe385) with the narrow but deep hydrophobic binding pocket of 
S100B(ββ) (see Fig. 1). It was suggested that Arg379 and Lys386 of p53 could form salt bridges 
with Glu45 and Glu86 of S100B(ββ), respectively32; however, exposed salt-bridges are rarely 
stabilizing33. In fact, p53 Lys386 and S100B(ββ) Glu86 are spatially close enough to make salt-
bridge contact only ~15% of the time in the NMR ensemble (see Fig. 2A). These observations 
together suggest that the p53/S100B(ββ) complex structure might not be as stable as previously 
thought. Interestingly, different levels of conformational instability of p53 have been observed 
consistently in recent atomistic simulations of the complex31;34;35 using different force fields 
including Amber ff9936, GROMOS 53a637 and GBSW implicit solvent38;39, although force field 
quality has been mainly invoked to rationalize such observations. 
To further examine potential fuzziness and structural basis of the p53-S100B(ββ) interaction, we 
performed extensive all-atom explicit solvent simulations using two of the best-tested empirical 
protein force fields, namely, CHARMM22/CMAP40-42 and Amber ff99SB43. Initiated from 
diverse members of the NMR ensemble, five independent simulations of the complex were 
carried out, allowing a total of 1.0 μs effective sampling of the p53/S100B(ββ) interface. The 
resulting conformational ensemble supports significant heterogeneity in p53 conformation when 
bound to S100B(ββ). Interestingly, such a heterogeneous ensemble appears to be highly 
consistent with experimentally assigned intermolecular NOEs. Clustering analysis further 
demonstrated that many conformational sub-states co-existed in the bound state and each 
satisfied a different sub-set of NOEs. Importantly, the proposed fuzzy complex structure 
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ensemble appears to be capable of providing similar shielding of key p53 PTM sites and thus 
could support the inhibition of p53 activation via S100B(ββ) association. 
Results 
Conformational heterogeneity of the p53/S100B(ββ) interface 
The p53/S100B(ββ) complex as a whole was stable, with the total Cα RMSD remaining around 
~3 Å in all five independent 100-ns CHARRM production simulations (Fig. S2). All bound 
calcium ions remain intact throughout all simulations. However, the p53/S100B(ββ) binding 
interface were highly dynamic. As shown in Fig. 3A, the (self) Cα RMSD of the p53 peptide 
fluctuated between 2–3 Å in most simulations but could increase up to greater than 5 Å in some 
cases (3 out of the 10 independent interfaces). Large self RMSD values are strongly correlated 
with significant loss of helicity (e.g., see final snapshots shown in Fig. S1B). On the ensemble 
level (including the last 60 ns from all production trajectories), only the N-terminal region of p53 
(residues 375–383) remains highly helical (with ~75% helicity), but the last helix turn (residues 
384–387) is rarely formed (Fig. 3D).  The pervious experimental assignment of the p53 helical 
segment (376-387) was based on Hα chemical shift indexing and medium range NOE 
connectivity32. It is probable that the current simulation underestimates the helicity in the p53-
NRD C-terminus. On the other hand, absence of experimentally resolved αβi,i+3, αNi,i+3 medium 
range NOEs in the last helical turn appears to be consistent with at least reduced helicity in this 
region. Interestingly, the Cα binding RMSD of p53 (as defined in Methods) rapidly increased to 
around 4–8 Å in all simulations regardless of the starting conformations. Helix unfolding clearly 
contributes to the large p53 binding RMSD values observed; but large binding RMSD appears to 
more of a consequence of substantial changes in p53 binding mode.  
As illustrated in Fig. 4, helix unwinding at the p53-NRD C-terminus allows key nonpolar 
residues, including Leu383 and Phe385, to penetrate deeper into the hydrophobic binding pocket 
of S100B(ββ) and make more extensive intermolecular contacts (see Fig. 2). Importantly, these 
hydrophobic interactions appear to play a key role in anchoring p53-NRD at the interface; for 
example, even though the C-terminal segment is less helical (Fig. 3D), it displays smaller 
fluctuations (Fig. 3C). The p53-NRD N-terminus appears to be stabilized mainly by interactions 
between Arg379 with several Glu residues on S100(ββ), including Glu45, Glu46, Glu49 and 
Glu51 on the hinge between the second and third helices (see Fig. 2 and Table S1). The presence 
of multiple complimentary charges on the hinge appears to facilitate the p53-NRD N-terminus to 
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sample alternative orientations in the bound state, leading to large fluctuations observed in 
simulations (Fig. 3C). Such conformational heterogeneity reduces the entropy penalty of p53 
folding upon binding, and might help to explain the ability of p53-NRD to bind S100(ββ) with a 
dissociation constant KD ~ 23 μM44, despite having a small hydrophobic interface that is mainly 
anchored by a single hydrophobic residue (Leu383). Interestingly, although p53-NRD Lys386 
was proposed to provide another anchoring point by interacting with S100(ββ) Glu8632, it 
displays a strong tendency to remain solvated. In fact, solvation of Lys386 and deeper burial of 
hydrophobic side chains (particularly Leu383) appear to be two key driving forces that drive the 
observed changes in p53-NRD conformation. 
The above qualitative observations are further supported by comparing the residue-residue 
contact maps calculated from the NMR and simulated ensembles. The maps are shown in Fig. 2, 
with all contacts observed with >0.2 probabilities listed in Table S1. The contact analysis clearly 
shows that the simulated ensemble predicts the p53 segment centered at Leu383 and Phe385 to 
be involved in more extensive contacts than in the NMR ensemble, while either the very N- or C-
terminus (particularly Lys386) makes fewer stable contacts. Interestingly, the overall pattern of 
contacts calculated from the simulated ensemble appears more consistent with the set of 
experimentally resolved (weak) intermolecular NOEs (marked as red crosses in Fig. 2) than the 
one derived from the original NMR ensemble. For example, the NMR ensemble gives rise to a 
sparser contact map (Fig. 2A), with few or no residue-residue contacts in several regions where 
NOEs are experimentally observed (e.g., near S100B 44 – p53 385, S100B 55 – p53 383, and 
S100B 55 – p53 387). In contrast, the simulated ensemble yields significantly populated contacts 
in these regions (Fig. 2B). In addition, substantial conformational heterogeneity in the N-
terminal segment of p53-NRD in the bound state could explain an apparent paucity of resolvable 
intermolecular NOEs for this region (only three very week ones were resolved; see Table 1). The 
consensus sequence of S100B-binding proteins have been suggested to contain a positive charge 
followed by several hydrophobic residues44;45; however, the exact sequence pattern appears to 
allow large variance, such as (K/R)(L/I)xWxxIL45 or 
(K/R)(L/I)(P/S/N/D)(W/L/I)(S/D/L)x(L/I)(L/F)44. Such variance could suggest that 
conformational heterogeneity observed at the p53/S100B(ββ) interface might be present in 
complexes formed by other S100B-binding peptides.  
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Validation of the simulated ensemble: force field dependence and NOE violation analysis  
Importantly, the observed “fuzziness” in the p53/S100B(ββ) interface does not seem to be an 
artifact of the CHARMM22/CMAP force field. Substantial instabilities have been observed 
consistently in previous simulations of the complex using other force fields31;34;35. For example, 
p53-NRD was found to be very flexible and to unfold significantly in the bound state during a 
20-ns explicit solvent simulation in the Amber ff99 force field31. Allen et al. found that the C-
terminus of p53-NRD unfolded during one of their 100-ns explicit solvent simulations in the 
GROMOS 53a6 force field34. We have further verified the force field dependence using an 
additional 100-ns simulation of the complex in the Amber ff99SB force field43, which is 
arguably one of the best force fields optimized for simulating protein conformational equilibria46.  
The results, summarized in Fig. S3, are highly consistent with the observations from the 
CHARMM simulations. Specifically, the p53 helix was also observed to unfold substantially, 
especially at the C-terminus, to allow more extensive hydrophobic contacts with S100B(ββ) (Fig. 
S3B). Both N- and C-termini of p53-NRD remains highly dynamic in the S100B(ββ)-bound 
state, and substantial conformational heterogeneity exists at the interface. There is also a notable 
resemblance between the residue-residue contact maps shown in Fig. S3D (Amber) and Fig. 2B 
(CHARMM), despite the substantial difference in amount of sampling. The genuineness of the 
observed dynamic p53/S100B(ββ) interface is further supported by an independent simulation of 
the bound state using the OPLS-AA/L force field published while the current work was under 
review47. It was also observed that p53-NRD underwent substantial helix unfolding, particularly 
at the C-terminus, to allow more extensive contacts of the p53 segment centered at Leu383 and 
Phe385 with S100B((ββ).  
As a more direct validation of the simulated ensemble, we back-calculated NOE-like distances 
between groups of atoms involved in all experimentally resolved intermolecular NOEs and 
compared them with the assigned upper bounds (see Methods).  The results are summarized in 
Table 1, and histograms of NOE-like distances between pairs of atom groups involved in six 
selected intermolecular NOEs are shown in Fig. 5. The analysis shows that the simulated 
ensemble as a whole is highly consistent with the experimental NOE set, with only 6 of the 33 
intermolecular NOEs violated by over 0.5 Å and only two violated by >2.0 Å. Both severely 
violated NOEs involve either Arg379 or Lys386, which, as discussed above, have a strong 
tendency to become solvent-exposed and likely drive the observed conformational changes (see 
Fig. 4). Importantly, substantial conformational dynamics and heterogeneity persisted throughout 
the simulations after initial relaxation, manifested as large fluctuation in NOE-like distances over 
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time (see Fig. S4) and divergence in the histograms of NOE-like distances calculated from 
different trajectories (Fig. 5). It should be emphasized that consistency with the experimental 
NOE restraints, although an important validation, is not sufficient to establish the correctness of 
the entire heterogeneous ensemble due to underdetermination23. In addition, because of the r-6 
averaging nature of NOE, calculated (or measured) ensemble-averaged NOE distances are not 
sensitive to conformations with much larger distances within the ensemble. 
Clustering analysis: existence of multiple conformational sub-states 
The average conformations of 8 largest clusters of the simulated ensemble identified by k-mean 
clustering using p53 binding Cα RMSD are shown in Fig. 6. These average structures further 
illustrate the broad manifold of conformational sub-states sampled by p53-NRD in the bound 
state. The p53 conformation itself appears to be somewhat similar in these clusters, with a rather 
stably formed helix at the N-terminus followed by a coiled C-terminal tail; however, substantial 
differences exist in the orientation of p53-NRD and specific interactions that it forms with 
S100B(ββ). The p53 peptide appears to pivot around Leu383, which forms many contacts with 
residues in the hydrophobic binding pocket of S100B(ββ) (see Fig. 2 and Table S1). The more 
helical N-terminus, stabilized mainly by electrostatic interactions, however, can sample many 
alternative orientations as represented by these clusters.  
We have further performed NOE violation analysis on sub-ensembles of structures that belong to 
the 10 most populated clusters. The results are summarized in Fig. 7. Several interesting 
observations can be made. First, all intermolecular NOEs are satisfied by two or more of the 10 
largest clusters, including those that are (severely) violated on the whole ensemble level (e.g., 
R379-K48 and K386-L44; see Table 1). Second, only a fraction of NOEs (6 out of 31) is 
consistently satisfied by all clusters analyzed, and these NOEs mainly involve Leu383 and the 
neighboring Met384. This is consistent with the structural analysis showing that the segment 
around Leu383 anchors the p53/S100B(ββ) interface. The third and arguably the most interesting 
observation is that most intermolecular NOEs are satisfied only by a few clusters. This result 
illustrates one of the major challenges in structural characterization of dynamic protein states, 
including both unbound IDPs and fuzzy complexes: That structural restraints derived from 
ensemble methods such as NMR or FRET often reflect conformational features that do not 
necessarily co-exist in the same conformational sub-state. This, again, highlights the importance 
of properly recognizing and representing fuzzy complexes in structural studies of IDP 
interactions. 
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Access to p53 PTM sites: inhibition of p53 activity 
To examine how effectively the simulated heterogeneous ensemble can hinder access to PTM 
sites in p53-NRD, we analyzed the average buried surface areas of p53 residues. The results, 
shown in Fig. 8, demonstrate that the profiles of residue buried surface areas from the NMR and 
simulated ensembles are very similar. Key PTM sites within p53-NRD include two 
phosphorylation sites (Ser376 and Thr377) and two acetylation sites (Arg379 and Lys386). 
Clearly, all these PTM sites except Thr377 remain sterically hindered despite the dynamic nature 
of p53-NRD in the simulated bound state. An important difference is that Thr377 becomes fully 
solvent-exposed and could potentially be phosphorylated by protein Kinase C (PKC); however, 
the helical state of the p53-NRD N-terminal segment, coupled with steric shielding of the 
neighboring residues, is likely sufficient to prevent access of Thr377 to the PKC active site for 
efficient phosphorylation. In addition, previous in vitro experiments have showed that either 
S376A or T377A alone could reduce p53 activity to a level that might be achieved by co-
transfection of S100B(ββ) (~50%)48. Therefore, the proposed heterogeneous ensemble could 
fully support S100(ββ) inhibition of p53 activity.  
Discussion 
Recent recognition of the prevalence of intrinsic disorder in biology has drastically expanded the 
perception of how protein structure may mediate function. Substantial progress has been made in 
understanding the structural basis and molecular mechanisms of IDP function, but mainly in the 
context of coupled binding and folding that involve well-structured bound states10;12;13. Examples 
have also emerged to suggest the generality and importance of structural disorder (or 
“fuzziness”) in the bound state of IDPs14;15. This is an important recognition that requires new 
ways of thinking about and studying IDP interaction and regulation. In particular, conformational 
ensembles are necessary for describing dynamic bound states, and conventional restrained 
molecular dynamics-based structural calculation protocols are no longer applicable. However, 
important challenges exist in calculating heterogeneous structure ensembles, and this is mainly 
due to the fundamental limitation that ensemble-averaged properties alone do not provide 
sufficient constraint (information) to uniquely define representative structure ensembles for 
heterogeneous protein states16;21. Instead, with important advances in protein force fields and 
sampling methodologies in recent years, physics-based atomistic simulations may provide an 
effective alternative means to generate de novo structural ensembles of disordered proteins 
states49.  
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For the case of the p53/S100B(ββ) complex, analysis of the NMR data and calculated structure 
ensemble suggests that the p53/S100B(ββ) interface is highly dynamic. Extensive atomistic 
explicit solvent simulations were performed using two state-of-the-art empirical protein force 
fields, which consistently revealed substantial heterogeneity in the p53-NRD conformation and 
how it binds with S100B(ββ). Specifically, helix unwinding at the p53-NRD C-terminus allows 
key hydrophobic residues (Leu383 and Phe385) to make more extensive contacts with 
S100B(ββ); the N-terminal segment, although highly helical, displays great flexibility in its 
packing with S100B(ββ). Additional NMR experiments, particularly relaxation measurements, 
will be necessary to provide direct experimental evidence on the dynamic nature of the 
S100B(ββ)-bound state of p53-NRD. Nonetheless, the simulated dynamic ensemble is highly 
consistent with experimental intermolecular NOE restraints, and provides similar shielding of 
key PTM sites in p53-NRD to support S100B(ββ) inhibition of p53 activity. The simulation thus 
offers a plausible alternative structural interpretation of how S100B(ββ) regulate p53 activity, 
and provides new insights for design of rational strategies for modulating this interaction for 
cancer therapy. The current study also demonstrates the importance and efficacy of an integrated 
computational and experimental strategy for understanding fuzzy complexes.   
Methods 
Explicit solvent simulations 
The NMR ensemble (PDB: 1dt732) consists of 40 structures and each contains two p53-NRD 
(residues 369-388) in complex with a Ca2+-loaded S100B(ββ) dimer. Five diverse conformers 
were first selected based on mutual backbone root-mean-square distances (RMSDs). The 
selected models were models 1, 21, 23, 30 and 31 from the NMR ensemble (see Fig. S1). These 
structures were then used to generate the initial configurations for independent simulations to 
facilitate conformational sampling. The NMR study showed that the N-terminal segment of p53-
NRD (residues 369–373) remained disordered and had little interaction with S100B(ββ); 
therefore, only residues 374–388 of p53 (sequence: GQ STSRH KKLMF KTE) were included in 
simulations. Removing the extended C-terminal tail also allowed ~25% smaller water boxes to 
be used. The truncated complex (including all four bound calcium ions) was solvated in TIP3P 
explicit water. Nine free calcium ions were added to neutralize the total charge. The final 
solvated system contains ~25,000 atoms in a periodic rectangular box of ~73 Å × 63 Å × 55 Å. 
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All five solvated initial conformations were equilibrated in CHARMM50;51 using multiple stages 
of energy minimization and constant pressure/temperature (NPT) simulation with gradually 
reducing harmonic positional restraints on the complex. The CHARMM22/CMAP force field40-42 
was used. After equilibration, five 100-ns NPT production simulations were performed at 300 K 
and under atmospheric pressure. To prevent global tumbling of the complex (such that a 
rectangular periodic box could be used), weak harmonic positional restraints with a force 
constant of 0.1 kcal/mol/Å2 were placed on the backbone heavy atoms of S100B(ββ) that were at 
least 10 Å away from any p53 atoms. These harmonic restraints are not expected to affect 
sampling of p53 conformation and interaction, because the S100B(ββ) dimer should remain 
stably folded with or without bound p5332. SHAKE52 was applied to constrain the lengths of all 
bonds involving hydrogen atoms, and a 2.0-fs dynamic time step was used. Particle Mesh Ewald 
(PME) was used to treat the long-range electrostatic interactoins53, and the van der Waals 
interactions were smoothly switched off from 12 to 13 Å. Snapshots were saved every 2 ps 
during the production simulations. Because there are two independent p53/S100B(ββ) interfaces 
in the system, five 100-ns simulations together yield a total of 1.0 μs effective sampling of the 
p53/S100B(ββ) interaction.  
To examine the force field dependence, the minimized structure model 1 of the NMR ensemble 
was also used to initiate an independent simulation in the Amber ff99SB force field43, performed 
using GROMACS54. The protein complex was solvated in a TIP3P cubic box with sides of 70 Å.  
Counter ions were added to the system using genion program include with GROMACS program 
suite. All bonds involving hydrogen atoms were restrained using the SHAKE. PME was used to 
treat long-range electrostatics, and van de Waals interactions were smoothly switched off at 12 
Å.  The system was energy minimized, followed by a 20-ns equilibration with a 2-fs time-step.  
The production simulation was performed for 100 ns.  The simulation trajectory was processed 
to remove periodic boundary wrapping and converted to the CHARMM format for analysis. 
Structural and Clustering Analysis 
All structural and clustering analysis were performed using CHARMM, the Multiscale Modeling 
Tools for Structural Biology (MMTSB) toolset55, and in-house scripts. Molecular visualization 
was generated using VMD56. Residue helicity was calculated using the COOR SECS module. 
Evolution of RMSD values of various segments, together with helicity analysis, suggests that the 
complex reached some type of (local) equilibrium after 20-40 ns (e.g., see Fig. S2 and Fig. 3).  
As such, conformations sampled during the last 60 ns of all five CHARMM trajectories were 
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included in the simulated conformational ensembles of the complex. All clustering and NOE 
analysis were performed on this ensemble unless otherwise noted. For clustering, the simulated 
ensemble was first under-sampled by only including snapshots every 100 ps during the last 60 ns 
of each production trajectory. Each snapshot was then split to generate two independent 
monomeric p53/S100B(ββ) complex structures. The resulting 6000-member ensemble was 
clustered using the fixed radius clustering algorithm as implemented in the 
MMTSB/enscluster.pl tool (with –kclust option). The distance between conformers for clustering 
was provided by p53 Cα RMSD, which was calculated by first aligning the whole monomeric 
complex using the backbone atoms of S100B(ββ). The RMSD values as calculated reflect 
differences in both internal conformation and the binding pose of p53-NRD, and will be referred 
to as “binding RMSD” for the rest of the text. The cutoff radius used in k-mean clustering was 
empirically selected to be 5 Å. Further NOE and helicity analysis was performed for each of the 
10 most populated clusters, which presumably represent key sub-states sampled by p53 when 
bound to S100B(ββ). It is important to emphasize that conformational sampling achieved in 
multiple 100-ns explicit solvent simulations remains limited and that the final ensemble as 
constructed without reweighing independent trajectories is not a rigorous Boltzmann ensemble; 
therefore, all calculated conformational properties should be considered semi-quantitative, if not 
only qualitative, estimates. 
NOE Violation Analysis 
The simulated ensemble was validated mainly through NOE violation analysis. For this, the 
original NMR restraint data files were downloaded from the direct link provided with the Protein 
Data Bank entry 1dt7, which included 33 unique intermolecular NOEs for each p53 peptide (see 
Table 1). Coordinates of all the atoms involved in each NOE assignment were extracted from the 
production trajectories. At each time point, NOE-like distances between two selected atom 
groups were calculated using the r-6 summation scheme57,  
, 
where rij is the distance between atoms i from one atom selection and j from the other as 
specified in the experimental NOE restraint set. The ensemble (time) averaged NOE-like 
distances were then calculated as:  
	 , 
13 
where <> represent averaging over all (time) snapshots included in a particular ensemble. Note 
that the r-6-weighted nature of NOE averaging renders rNOE highly sensitive to small population 
of conformations with small rNOE(t) and at the same time rather insensitive to fraction of 
populations with significantly larger rNOE(t). We also note that protein internal dynamics can 
modulate the cross relaxation rates and can be included in NOE analysis of continuous MD 
trajectories43;58. The effects of angular fluctuation are ignored in the above analysis due to the 
need to include conformations sampled from multiple independent simulations. Nonetheless, 
comparative analysis using the model 1 trajectory suggests that neglecting ps-ns timescale 
motions in NOE analysis only leads to limited under-estimation of the back-calculated NOE 
distances (see Table S3 and the following text). 
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Table 1. Summary of NOE violation analysis of the simulated ensemble.  
Atom Pairs Rnmr (Å) a Rsim (Å) a Violation (Å) 
L383 HD* - L3 HD* b 6.0 6.2 0.2 
L383 HD* - M7 HE* b 5.0 6.2 1.2 
Q375 HB* - E51 HG* 6.0 7.0 1.0 
R379 HB* - K48 HG* 5.0 7.0 2.0 
R379 HD* - V52 HG2* 6.0 3.0 − 
L383 HD* - V52 HG2* 6.0 3.1 − 
L383 HD* - V56 HG* 5.0 2.2 − 
L383 HD* - V77 HG2* 6.0 7.3 1.3 
L383 HD* - M79 HE* 3.3 3.1 − 
L383 HB* - M79 HE* 5.0 4.0 − 
L383 HD* - V80 HG2* 4.2 2.9 − 
L383 HD* - V80 HG1* 5.0 3.4 − 
L383 HD* - T82 HG2* 6.0 7.1 1.1 
L383 HB* - A83 HB* 5.0 3.1 − 
L383 HD* - A83 HB* 5.0 4.7 − 
M384 HB* - K55 HG* 6.0 4.5 − 
M384 HG* - V56 HG* 6.0 2.3 − 
M384 HE* - V56 HG* 6.0 2.8 − 
M384 HE* - L44 HD* 6.0 3.4 − 
F385 HE* - M79 HE* 6.0 4.9 − 
F385 HZ - M79 HE* 6.0 6.5 0.5 
F385 HE* - V80 HG2* 6.0 3.0 − 
F385 HZ - V80 HG2* 6.0 4.3 − 
F385 HD* - V80 HG1* 6.0 5.0 − 
F385 HE* - A83 HB* 5.0 4.1 − 
F385 HZ - A83 HB* 6.0 3.3 − 
F385 HZ - L44 HD* 6.0 3.0 − 
K386 HD* - T82 HG2* 5.0 3.4 − 
K386 HG* - T82 HG2* 6.0 4.4 − 
K386 HD* - L44 HD* 6.0 8.4 2.4 
T387 HG* - K55 HG* 5.0 4.2 − 
E388 HG* - M79 HE* 5.0 4.6 − 
E388 HG* - T82 HG2* 6.0 4.2 − 
a  Rnmr: experimentally assigned upper bound;  Rsim:  ensemble-averaged NOE-like distance calculated from 
the simulated ensemble. 
b Involving p53-S100B(ββ) side chains across the symmetric dimer interface. 
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Figure Legends 
 
 
Figure 1. Cartoon representation of the p53/S100B(ββ) complex structure ((PDB:1dt7, model 1). 
Only one monomer of the dimeric complex is highlighted in solid colors. Bound calcium ions are 
displayed as pink spheres. Key residues of p53 are shown in thick sticks and labeled. All 
S100B(ββ) residues involved in NOE contacts with the p53 peptide highlighted are shown in thin 
sticks. Note that two of the intermolecular NOEs involve S100B(ββ) side chains across the 
symmetric dimer interface (Leu3 and Met7; see Table 1). Both residues locate deep at the bottom 
of the hydrophobic pocket where p53 binds. Four helices (H1-4) of  S100B(ββ), together with 
the hinge between H2 and H3 are also labeled. 
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Figure 2. Intermolecular residue contact maps computed from A) the NMR ensemble (PDB: 
1dt7) and B) the simulated ensemble. A contact is considered formed when the shortest distance 
between heavy atoms of two residues is no greater than 4.2 Å. The contacts are color-coded 
according to their probabilities. The red crosses mark the residue pairs that are involved in the 
experimentally resolved intermolecular NOEs (also see Table 1). 
 
 
Figure 3. Conformational properties of p53 in the p53/S100B(ββ) complex. A) Cα (self) RMSD, 
B) binding RMSD and C) root mean square fluctuation (RMSF) of p53 (first monomer in the 
complex) calculated from five independent 100-ns simulations, initiated from NMR ensemble 
model 1 (red), 21 (green), 23 (blue), 30 (pink), and 31 (cyan), respectively. The RMSF profiles 
21 
were calculated by first aligning all snapshots using all Cα atoms. D) Averaged residue helicity 
profiles calculated from the NMR (solid black) and simulated ensembles (dashed black). A few 
representative helicity profiles for individual p53 monomers in various production simulations 
are also shown: red (first monomer from model 1 trajectory), green and pink (p53 monomers 
from model 21 trajectory), and blue trace (second p53 monomer from model 23 trajectory). Note 
that most other monomers yield helicity profiles similar to the red trace. 
 
 
Figure 4. Two representative simulated conformations of p53 bound to S100(ββ). The two p53 
monomers in the final snapshot of the 100-ns CHARMM simulation initiated from NMR 
ensemble model 1 are used (also see Fig. S1). S100B(ββ) is shown in yellow trace and p53 
peptides in purple cartoon. Several key p53 residues are shown in sticks. The initial p53 
conformations are also plotted in transparent green cartoon for reference. 
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Figure 5. Histograms of NOE-like distances between pairs of atom groups involved in six 
selected intermolecular NOEs. All selected NOEs involve at least one of the key p53 residues for 
binding S100B(ββ), namely, Arg379, Leu383, and Phe385. These histograms were calculated 
from the last 60 ns of five independent simulations initiated from selected NMR models. The 
color-coding is the same as in Fig. 3A. The black dashed lines mark the experimentally assigned 
NOE upper bounds. Only the R379HB-K48HG NOE is violated (by 2.0 Å) when all five 
simulations are included (see Table 1). 
 
23 
 
Figure 6. Average structures and populations of the eight largest clusters of the simulated 
ensemble. S100B(ββ) is shown in yellow trace and the p53 peptide in purple cartoon. Several 
key p53 residues are shown in sticks.  The NMR structure (model 1) is shown in the middle for 
reference. All conformations are aligned using all Cα atoms of S100B(ββ). 
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Figure 7. Summary NOE violation analysis of the top ten most populated clusters of the 
simulated ensemble. The identities of intermolecular NOEs are labeled on the y-axis. These 
NOEs are arranged in the same order as in Table 1. The analysis does not include the two NOEs 
that involve residues across the symmetric dimer interface. Red blocks mark NOEs that are 
violated by at least1.0 Å by individual clusters. 
 
 
Figure 8: Average buried (solvent-accessible) surface areas of p53 residues from the NMR (red 
bars) and simulated (green bars) ensembles. The errors bars shown are standard deviations 
calculated from either the 40 members of the NMR ensemble or the five independent 
simulations. 
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Figure S1. A) Five diverse models selected from the NMR ensemble (PDB: 1dt7).  From top left to 
right, the model numbers are 1st, 21nd, 23rd, 30th, and 31st. B) Final snapshots after 100 ns 
production simulation in the CHARMM22/CMAP force field. S100B((ββ) is shown in yellow trace 
and p53 peptides in purple cartoon representations. Side chains of key p53 residues (R379, L383, 
and F385) are shown in sticks. All initial and final snapshots are displayed in the same orientation 
(by aligning the Cα atoms of S100B). Waters and ions are not shown for clarity. 
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Figure S2. A) Cα RMSD of the whole complex from their corresponding initial conformations 
during five 100-ns production simulations, initiated from NMR ensemble model 1 (red), 21 
(green), 23 (blue), 30 (pink), and 31 (cyan), respectively. B) Cα RMSF of S100B(ββ) (first 
monomer of the dimer) calculated from the last 60 ns of the production simulations. The curves 
are color coded in the same fashion as in panel A.  
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Table S1. Intermolecular contacts observed with >0.2 probabilities from the NMR and 
simulated ensembles. 
NMR (PDB: 1dt7) Simulation 
Residue Pairs Probabilities Residue Pairs Probabilities 
Ser 376 Lys 48 0.24 Ser 376 Val 52 0.20 
Thr 377 Glu 51 0.65 Arg 379 Glu 45 0.67 
Thr 377 Val 52 0.26 Arg 379 Glu 46 0.23 
Arg 379 Glu 45 0.94 Arg 379 Glu 49 0.35 
Arg 379 Glu 46 0.26 Arg 379 Val 52 0.44 
Arg 379 Ile 47 0.23 His 380 Val 52 0.42 
Arg 379 Lys 48 0.48 His 380 Lys 55 0.54 
His 380 Glu 45 0.46 His 380 Val 56 0.46 
His 380 Val 52 0.99 His 380 Thr 59 0.35 
His 380 Lys 55 0.69 Lys 382 Glu 45 0.30 
His 380 Val 56 0.40 Lys 382 Ala 83 0.22 
Leu 383 Glu 45 0.30 Leu 383 Leu 44 0.76 
Leu 383 Phe 76 0.78 Leu 383 Glu 45 0.40 
Met 384 Lys 55 0.54 Leu 383 Ile 47 0.47 
Phe 385 Ala 83 1.00 Leu 383 Val 52 0.30 
Phe 385 Glu 86 0.45 Leu 383 Val 56 0.49 
Lys 386 Gln 71 0.39 Leu 383 Phe 76 0.26 
Lys 386 Phe 76 0.25 Leu 383 Met 79 0.38 
Lys 386 Met 79 1.00 Met 384 Val 52 0.22 
Lys 386 Val 80 0.60 Met 384 Lys 55 0.26 
Lys 386 Thr 82 0.30 Met 384 Val 56 0.65 
Lys 386 Ala 83 0.39 Met 384 Thr 59 0.56 
Thr 387 Thr 59 0.20 Met 384 Phe 76 0.29 
Thr 387 Met 79 0.36 Met 384 Met 79 0.67 
Glu 388 Gln 71 0.66 Phe 385 Leu 44 0.27 
   Phe 385 Met 79 0.42 
   Phe 385 Ala 83 0.48 
   Lys 386 Met 79 0.28 
   Thr 387 Thr 59 0.21 
   Thr 387 Met 79 0.38 
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Figure S3. A) Cα RMSD of the whole complex (red) and first p53 monomer (black) from the 
initial conformation and B) the final snapshot from the 100-ns production simulation in the 
Amber99SB force field. Note that the RMSD values of p53 were calculated by first aligning the 
backbone heavy atoms of S100B(ββ) with the reference (initial) conformation (referred to as 
binding RMSD in the main text).  C) Averaged residue helicity calculated by the Amber99SB 
trajectory (red trace) in comparison to the CHARMM ensemble (green trace, see Fig. 3 of the 
main text). D) Intermolecular residue contact maps computed from the Amber99SB trajectory. 
Both p53 monomers were included in calculation of the helicity profile and contact map shown.  
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Table S2: Summary of NOE violation analysis of the Amber99SB trajectory. 
Atom Pairs Rnmr (Å) a Rsim (Å) a Violation (Å) 
L383 HD* - L3 HD* b 6.0 6.8 0.8 
L383 HD* - M7 HE* b 5.0 5.8 0.8 
Q375 HB* - E51 HG* 6.0 4.9 − 
R379 HB* - K48 HG* 5.0 9.0 4.0 
R379 HD* - V52 HG2* 6.0 3.3 − 
L383 HD* - V52 HG2* 6.0 3.4 − 
L383 HD* - V56 HG* 5.0 2.1 − 
L383 HD* - V77 HG2* 6.0 6.8 0.8 
L383 HD* - M79 HE* 3.3 2.7 − 
L383 HB* - M79 HE* 5.0 4.0 − 
L383 HD* - V80 HG2* 4.2 2.7 − 
L383 HD* - V80 HG1* 5.0 2.8 − 
L383 HD* - T82 HG2* 6.0 8.0 2.0 
L383 HB* - A83 HB* 5.0 4.1 − 
L383 HD* - A83 HB* 5.0 4.9 − 
M384 HB* - K55 HG* 6.0 2.6 − 
M384 HG* - V56 HG* 6.0 7.2 1.2 
M384 HE* - V56 HG* 6.0 2.7 − 
M384 HE* - L44 HD* 6.0 3.0 − 
F385 HE* - M79 HE* 6.0 7.4 1.4 
F385 HZ - M79 HE* 6.0 4.1 − 
F385 HE* - V80 HG2* 6.0 5.1 − 
F385 HZ - V80 HG2* 6.0 10.0 4.0 
F385 HD* - V80 HG1* 6.0 7.1 1.1 
F385 HE* - A83 HB* 5.0 8.0 2.0 
F385 HZ - A83 HB* 6.0 4.4 − 
F385 HZ - L44 HD* 6.0 6.1 1.1 
K386 HD* - T82 HG2* 5.0 7.7 1.7 
K386 HG* - T82 HG2* 6.0 4.8 − 
K386 HD* - L44 HD* 6.0 5.0 − 
T387 HG* - K55 HG* 5.0 7.3 2.3 
E388 HG* - M79 HE* 5.0 8.9 3.9 
E388 HG* - T82 HG2* 6.0 7.2 1.2 
a  Rnmr: experimentally assigned upper bound;  Rsim:  ensemble-averaged NOE-like distance calculated 
from the simulated ensemble. 
b Involving p53-S100B(ββ) side chains across the symmetric dimer interface. 
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Figure S4. Time evolution of NOE-like distances between pairs of atom groups involved in six 
selected intermolecular NOEs during the last 60 ns of production simulations. The color-coding is 
the same as in Fig. 3A. The black lines mark the experimentally assigned NOE upper bounds. 
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Table S3: NOE distances calculated for monomer 1 from the last 60 ns of mode 1 trajectory using 
simple r-6 averaging ( Rsim
rigid ) and by considering the full effects of internal dynamics (see the 
following text for a brief summary of the analysis method). a, b: See Table S2. 
Atom Pairs Rnmr (Å) a Rsim
rigid  (Å)  S2  τe (ps) Rsimdynamic / Rsimrigid  
L383 HD* - L3 HD* b 6.0 6.8 0.957  5516  1.006 
L383 HD* - M7 HE* b 5.0 7.6 0.916  2783  1.014 
Q375 HB* - E51 HG* 6.0 7.4 0.708  2792  1.055 
R379 HB* - K48 HG* 5.0 6.4 0.706  3313  1.053 
R379 HD* - V52 HG2* 6.0 2.9 0.521  1459  1.130 
L383 HD* - V52 HG2* 6.0 3.0 0.580  3455  1.081 
L383 HD* - V56 HG* 5.0 2.0 0.848  2176  1.028 
L383 HD* - V77 HG2* 6.0 7.8 0.951  4216  1.007 
L383 HD* - M79 HE* 3.3 2.8 0.643  1995  1.079 
L383 HB* - M79 HE* 5.0 4.2 0.704  1979  1.062 
L383 HD* - V80 HG2* 4.2 4.3 0.811  2789  1.033 
L383 HD* - V80 HG1* 5.0 5.1 0.845  1272  1.032 
L383 HD* - T82 HG2* 6.0 9.0 0.938  2426  1.010 
L383 HB* - A83 HB* 5.0 5.7 0.876  3154  1.020 
L383 HD* - A83 HB* 5.0 7.2 0.878  2599  1.021 
M384 HB* - K55 HG* 6.0 7.0 0.798  2936  1.035 
M384 HG* - V56 HG* 6.0 2.4 0.748  947.6  1.058 
M384 HE* - V56 HG* 6.0 2.9 0.721  1647  1.060 
M384 HE* - L44 HD* 6.0 4.3 0.823  3650  1.029 
F385 HE* - M79 HE* 6.0 7.2 0.355  871.3  1.232 
F385 HZ - M79 HE* 6.0 5.1 0.361  809.7  1.247 
F385 HE* - V80 HG2* 6.0 5.2 0.432  974.0  1.189 
F385 HZ - V80 HG2* 6.0 8.2 0.323  2171  1.209 
F385 HD* - V80 HG1* 6.0 5.6 0.344  2310  1.191 
F385 HE* - A83 HB* 5.0 4.0 0.412  1033  1.200 
F385 HZ - A83 HB* 6.0 3.4 0.415  618.4  1.205 
F385 HZ - L44 HD* 6.0 4.6 0.361  809.7  1.247 
K386 HD* - T82 HG2* 5.0 3.3 0.832  1831  1.033 
K386 HG* - T82 HG2* 6.0 3.4 0.782  2321  1.041 
K386 HD* - L44 HD* 6.0 9.3 0.904  1467  1.018 
T387 HG* - K55 HG* 5.0 9.0 0.815  2870  1.032 
E388 HG* - M79 HE* 5.0 7.9 0.744  1025  1.059 
E388 HG* - T82 HG2* 6.0 9.1 0.870  2213  1.023 
Influence of internal dynamics on the calculated NOE distances 
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We largely followed the approach laid out in Bruschweiler et al. (1992) [1] for analyzing the 
influence of internal dynamics on the NOE distances calculated from the last 60 ns of the 100 ns 
CHARMM trajectory initiated from model 1 of the NMR ensemble (see the main text). The 
analysis was performed using a slightly modified version of the CHARMM NMR module [1,2]. 
Briefly, we assumed that the internal and overall motions of the protein are uncoupled, and only 
internal correlation functions corresponding to individual proton-proton vectors were calculated 
from the MD trajectory. Most intermolecular NOEs involve groups of multiple hydrogen atoms, 
particularly one or two methyl groups. Following the work of Schneider et al. (1999) [3], we 
represented each proton group using the heavy atom nearest to its center of mass to calculate a 
single internal correlation function for each pairs of proton groups. The generalized order 
parameters, S2, and effective internal correlation time constants, τe, are given in Table S3. Given 
the spectral densities Jij(ω), the cross-relaxation rates between spines i and j are given as, 
   

ijdynamic  5 
4h2 6Jij (2 )  Jij (0) ,     (1) 
where ω is the Larmor frequency and γ is the gyromagnetic ratio of protons. In the limit of rigid 
proteins, the spectral density is given by the Fourier transform of the overall tumbling correlation 
function (assuming isotropic tumbling), 
   Jij
rigid ( )  rij
6
2
R
1 2R2  ,      (2) 
where τR is the overall molecular tumbling time constant. The corresponding cross-relaxation 
rates in the limit of rigid molecular, ijrigid , can be then calculated by substituting Eq. 2 into Eq. 1. 
The effects of internal dynamics on the back-calculated NOE distances are then estimated as: 
   Rsim
dynamic
Rsim
rigid 
ijrigid
ijdynamic




1/ 6
.       (3)  
The molecular tumbling time was set to be 12.0 ns based on the HYDRONMR analysis of the 
truncated PDB structure (model 1) [4]. The length of internal correlation functions was set to 
12.0 ns (20% of the trajectory length). All relaxation rates were calculated assuming a 600 MHz 
proton frequency as used in the experimental study [5]. 
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